<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 a.m.-9:00 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td>1:30 p.m.-5:50 p.m.</td>
<td>Educational Session</td>
</tr>
<tr>
<td>1:30 p.m.-2:30 p.m.</td>
<td>Mining the TCGA</td>
</tr>
<tr>
<td></td>
<td>Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>2:30 p.m.-3:30 p.m.</td>
<td>Cell lines as ovarian cancer models: Insights from molecular profiles in TCGA and CCLE</td>
</tr>
<tr>
<td></td>
<td>Nikolaus Schultz, Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>3:30 p.m.-3:50 p.m.</td>
<td>Break</td>
</tr>
<tr>
<td>3:50 p.m.-4:50 p.m.</td>
<td>Biomarker development</td>
</tr>
<tr>
<td></td>
<td>David G. Huntsman, BC Cancer Foundation, Vancouver, BC, Canada</td>
</tr>
<tr>
<td>4:50 p.m.-5:50 p.m.</td>
<td>Bringing a drug from development to the clinic</td>
</tr>
<tr>
<td></td>
<td>Carol A. Aghajanian, Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>5:50 p.m.-7:00 p.m.</td>
<td>Dinner on Own</td>
</tr>
<tr>
<td>7:00 p.m.-9:00 p.m.</td>
<td>Keynote Addresses</td>
</tr>
<tr>
<td>7:00 p.m.-8:00 p.m.</td>
<td>40 years of developmental therapeutics in ovarian cancer</td>
</tr>
<tr>
<td></td>
<td>Carol A. Aghajanian, Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>8:00 p.m.-9:00 p.m.</td>
<td>In tumor screening for novel targets in papillary serous ovarian cancer</td>
</tr>
<tr>
<td></td>
<td>David M. Livingston, Dana-Farber Cancer Institute, Boston, MA</td>
</tr>
<tr>
<td>9:00 p.m.-10:30 p.m.</td>
<td>Dessert Reception</td>
</tr>
</tbody>
</table>
Thursday, September 19

7:00 a.m.-8:00 a.m. Continental Breakfast

8:00 a.m.-8:10 a.m. Welcome Note and Conference Overview
Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY

8:10 a.m.-10:10 a.m. Session 1: The Origins of Ovarian Cancer
Session Chairperson: Robert J. Kurman, Johns Hopkins Medical Institutes, Baltimore, MD

8:10 a.m.-8:40 a.m. A dualistic model of ovarian carcinogenesis
Robert J. Kurman

8:40 a.m.-9:10 a.m. Discovering the distal fallopian tube as the origin for high-grade serous ovarian cancer
Ronny I. Drapkin, Dana-Farber Cancer Institute, Boston, MA

9:10 a.m.-9:40 a.m. Murine models of non-serous ovarian cancer: Effects of mutant Trp53, Pik3ca, and Arida1a in a model of endometrioid carcinoma based on Wnt and PI3K/Akt pathway defects
Kathleen R. Cho, University of Michigan Medical School, Ann Arbor, MI

9:40 a.m.-9:55 a.m. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in BRCA/P53 models*
Daniela Dinulescu, Brigham and Women’s Hospital, Boston, MA

9:55 a.m.-10:10 a.m. Cyclin E1 deregulation occurs early during fallopian tube tumorigenesis and promotes secretory cell transformation*
Alison Karst, Dana-Farber Cancer Institute, Boston, MA

10:10 a.m.-10:30 a.m. Break

*Short talks from proffered papers
10:30 a.m.-12:30 p.m. Session 2: Genomic Classification of Ovarian Cancer
Session Chairperson: James D. Brenton, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

10:30 a.m.-11:00 a.m. Determinants of clinical outcome in ovarian cancer
David D. Bowtell, Peter MacCallum Cancer Centre, Melbourne, Australia

11:00 a.m.-11:30 a.m. Discovering drivers in rare ovarian cancer subtypes
David G. Huntsman, BC Cancer Foundation, Vancouver, BC, Canada

11:30 a.m.-12:00 p.m. Pathway-directed therapy
Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY

12:00 p.m.-12:15 p.m. Oxidants and antioxidants in the follicular fluid in initiation of fimbriae carcinogenesis*
Hsuan-Shun Huang, Cervical Cancer Prevention Center, Tzu Chi University, Hualien, Taiwan

12:15 p.m.-12:30 p.m. DNA-PK inhibition resensitizes ovarian cancer cells to cisplatin in vivo and is associated with modulation of AKT pathway signaling*
Euan Stronach, Imperial College London, London, United Kingdom

12:30 p.m.-2:00 p.m. Free Time/Lunch on Own

2:00 p.m.-4:00 p.m. Session 3: High-Throughput Analysis in Ovarian Cancer
Session Chairperson: Sandra Orsulic, Cedars-Sinai Medical Center, Los Angeles, CA

2:00 p.m.-2:30 p.m. Comprehensive proteomic analyses of TCGA ovarian cancer specimens: Update from CPTAC
Karin D. Rodland, Pacific Northwest National Laboratory, Richland, WA

2:30 p.m.-3:00 p.m. Functional genomics of ovarian cancer
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX

3:00 p.m.-3:30 p.m. Using publicly available databases for the functional characterization of cancer genes
Sandra Orsulic, Cedars-Sinai Medical Center, Los Angeles, CA

*Short talks from proffered papers
3:30 p.m.-4:15 p.m. Keynote Address
Ovarian cancer: Time for a new paradigm
Robert F. Ozols, Fox Chase Cancer Center, Philadelphia, PA

4:30 p.m.-6:30 p.m. Poster Session A and Reception

Friday, September 20

7:00 a.m.-8:00 a.m. Continental Breakfast
Mentoring Roundtables

8:00 a.m.-10:00 a.m. Session 4: Therapeutic Opportunities from DNA Repair Deficiency
Session Chairperson: Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY

8:00 a.m.-8:30 a.m. The Fanconi anemia-BRCA pathway and chemosensitivity of cancer cells
Toshiyasu Taniguchi, Fred Hutchinson Cancer Research Center, Seattle, WA

8:30 a.m.-9:00 a.m. Exploiting the translational and functional opportunities for homologous recombination deficiency
Richard J. Edmondson, Newcastle University Medical School, Newcastle Upon Tyne, United Kingdom

9:00 a.m.-9:30 a.m. PARP inhibitors in ovarian cancer: Clinical trial update
Katherine Bell-McGuinn, Memorial Sloan-Kettering Cancer Center, New York, NY

9:30 a.m.-9:45 a.m. In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer*
Mariam Al Hilli, Mayo Clinic, Rochester, MN

9:45 a.m.-10:00 a.m. Ovarian cancers harbour defects in nonhomologous end joining resulting in error prone repair and resistance to rucaparib*
Aiste McCormick, Northern Institute for Cancer Research, Newcastle Upon Tyne, Tyne and Wear, United Kingdom

10:00 a.m.-10:30 a.m. Break

*Short talks from proffered papers
10:30 a.m.-12:30 p.m. **Session 5: Targeting Drug Resistance**  
*Session Chairperson: David G. Huntsman, BC Cancer Foundation, Vancouver, BC, Canada*

10:30 a.m.-11:00 a.m. **Targeting acquired platinum resistance in ovarian cancer**  
Hani Gabra, Imperial College London, London, United Kingdom

11:00 a.m.-11:30 a.m. **Targeting cancer stem cells to overcome chemotherapy resistance**  
Ronald J. Buckanovich, University of Michigan, Ann Arbor, MI

11:30 a.m.-12:00 p.m. **Targeting the methylome for epigenetic resensitization of ovarian cancer**  
Kenneth P. Nephew, Indiana University School of Medicine, Bloomington, IN

12:00 p.m.-12:15 p.m. **Targeting CD24+ ovarian cancer stem-like cells in a transgenic murine model of ovarian cancer restricts metastasis***  
Daniela Burgos-Ojeda, University of Michigan, Ann Arbor, MI

12:15 p.m.-12:30 p.m. **HNF1beta confers resistance to oxidative stress of ovarian clear cell carcinoma***  
Yasuaki Amano, Graduate School of Medicine, Kyoto University, Kyoto, Japan

12:30 p.m.-2:30 p.m. **Poster Session B and Lunch**

*Short talks from proffered papers*
2:30 p.m.-4:30 p.m. **Session 6: Clinical Implications of Intratumoral Heterogeneity**
*Session Chairperson: Hani Gabra, Imperial College London, London, United Kingdom*

2:30 p.m.-3:00 p.m. **Evolutionary dynamics of high-grade serous ovarian cancer genomes across anatomic space and time**
Sohrab Shah, BC Cancer Agency Vancouver Centre, Vancouver, BC, Canada

3:00 p.m.-3:30 p.m. **Intratumoral heterogeneity and drug response in high-grade serous carcinoma**
James D. Brenton, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

3:30 p.m.-4:00 p.m. **Analyzing the cellular basis for heterogeneity in serous ovarian carcinoma**
Benjamin G. Neel, University of Toronto Ontario Cancer Institute, Toronto, ON, Canada

4:00 p.m.-4:15 p.m. **Cellular heterogeneity of ovarian carcinoma cells and its impact on tumor behavior** *
Suha Naffar-Abu Amara, Harvard Medical School, Boston, MA

4:15 p.m.-4:30 p.m. **Intra- and intertumor heterogeneity in epithelial ovarian cancer: Consequences for biomarker-dependent stratification of therapies** *
Rachel O’Donnell, Northern Gynaecological Oncology Centre, Gateshead, United Kingdom

4:30 p.m.-5:30 p.m. **Panel Discussion: Survivorship Issues**
*Sponsored by the Foundation for Women’s Cancer*

Moderator : Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY

Panelists:

*Cancer Survivors:*
Patricia Goldman, Washington, DC
Jennie McGihon, Alexandria, VA

*Physician Scientists:*
David G. Huntsman, BC Cancer Foundation, Vancouver, BC, Canada
James D. Brenton, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

*Short talks from proffered papers*
Saturday, September 21

7:00 a.m.-8:00 a.m.  Continental Breakfast
   Mentoring Roundtables

8:00 a.m.-10:00 a.m.  Session 7: Tumor Microenvironment
   Session Chairperson: Sandra Orsulic, Cedars-Sinai Medical
   Center, Los Angeles, CA

8:00 a.m.-8:30 a.m.  Causes and consequences of cancer-associated
   thrombocytosis
   Anil K. Sood, The University of Texas MD Anderson Cancer
   Center, Houston, TX

8:30 a.m.-9:00 a.m.  Targeting the inflammatory cytokine network of serous
   ovarian cancer
   Frances R. Balkwill, Barts Cancer Institute, London, United
   Kingdom

9:00 a.m.-9:30 a.m.  Microenvironmental regulation of metastasis
   Ernst R. Lengyel, University of Chicago, Chicago, IL

9:30 a.m.-9:45 a.m.  Ovarian cancer cells activate the mesothelium in the
   peritoneal microenvironment promoting fibronectin
   production and the early steps of metastasis*
   Hilary Kenny, University of Chicago, Chicago, IL

9:45 a.m.-10:00 a.m.  Immunomodulatory effects of 5-Azacytidine in ovarian cancer
   cell lines*
   Katherine Chiappinelli, The Sidney Kimmel Comprehensive
   Cancer Center at Johns Hopkins University Medical School,
   Baltimore, MD

10:00 a.m.-10:15 a.m.  Break
10:15 a.m.-12:15 p.m.  Session 8: Immunotherapy on the Horizon  
Session Chairperson: George Coukos, University Hospital of Lausanne, Epalinges, Switzerland

10:15 a.m.-10:45 a.m.  Immunotherapy opportunities and challenges in ovarian cancer  
George Coukos

10:45 a.m.-11:15 a.m.  Protective immune networks in ovarian cancer  
Brad Nelson, BC Cancer Agency, Vancouver Island, BC, Canada

11:15 a.m.-11:45 p.m.  NY-ESO-1 targeted immunotherapy  
Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, NY

11:45 p.m.-12:15 p.m.  Combinatorial immunotherapy using whole tumor antigen: Evidence from phase I trials  
Lana E. Kandalaft, University of Pennsylvania School of Medicine, Philadelphia, PA

12:15 p.m.-12:30 p.m.  Closing Remarks and Departure